Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Study Syros' CDK7 Inhibitor With Tecentriq in BRAF-Mutated Colorectal Cancer Patients

NEW YORK – Syros Pharmaceuticals on Thursday said it has inked an agreement with Roche to supply its CDK7 inhibitor SY-5609 so that it may be studied with Roche's immune checkpoint inhibitor atezolizumab (Tecentriq) in a molecularly defined colorectal cancer patient population.

Under the terms of their agreement, Cambridge, Massachusetts-based Syros will supply SY-5609 for the Phase I/Ib INTRINSIC trial, which is exploring the activity of different targeted drugs or immunotherapies, among them atezolizumab, either as single agents or in combination regimens in colorectal cancer patients with molecularly aberrant tumors. Roche is conducting and financially supporting the trial, and will evaluate the safety, tolerability, and preliminary efficacy of SY-5609 and atezolizumab in BRAF-mutated colorectal cancer patients. Syros will receive access to the study data related to theSY-5609-atezolizumab combination and retain rights to SY-5609.

"We are pleased that Roche has chosen to study SY-5609 as part of its broader strategy to explore atezolizumab in combination with other targeted agents in defined colorectal cancer patient populations," said Syros CEO Nancy Simonian, adding that this Phase I/Ib trial will be the first clinical exploration of a CDK7 inhibitor with an immunotherapy.

Roche's rationale for combining atezolizumab with a SY-5609 is backed by preclinical data showing that CDK7 inhibition leads to DNA replication stress and genomic instability, which triggers an immune response that is further strengthened with the addition of an immune checkpoint inhibitor. Syros also presented preclinical data at the American Society of Clinical Oncology's annual meeting in June showing that SY-5609 had particularly robust activity in tumor models with BRAF mutations.